Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis

Company Overview

Fresenius SE & Co. KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions. Michael Sen has served as chief executive officer since 2022. The company previously operated through additional health care services businesses, including Vamed, before simplifying its portfolio around Kabi and Helios.

Key Stats

• Today's Range: $13.00 to $13.10
• 50-Day Range: $11.74 to $13.83
• 52-Week Range: $10.33 to $33.93
• Volume: 70,269 shs
• Average Volume: 122,698 shs
• Market Capitalization: $29.29 billion
• P/E Ratio: 16.46
• Dividend Yield: 1.54%
• Price Target: N/A
• Consensus Rating: Buy

Fresenius SE & Co. Stock Analysis - MarketRank™

Fresenius SE & Co. scored higher than 75% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Buy

Consensus Rating

Fresenius SE & Co. has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fresenius SE & Co. has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.48%

Earnings Growth

Earnings for Fresenius SE & Co. are expected to grow by 6.48% in the coming year, from $1.08 to $1.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fresenius SE & Co. is 16.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fresenius SE & Co. is 16.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.41.

Price to Book Value per Share Ratio

Fresenius SE & Co. has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Fresenius SE & Co. has been sold short.

Short Interest Ratio / Days to Cover

Fresenius SE & Co. has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fresenius SE & Co. has recently decreased by 96.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Fresenius SE & Co. pays a meaningful dividend of 1.57%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Fresenius SE & Co. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Fresenius SE & Co. is 25.32%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Fresenius SE & Co. will have a dividend payout ratio of 17.39% next year. This indicates that Fresenius SE & Co. will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.04

News Sentiment

Fresenius SE & Co. has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Fresenius SE & Co. this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fresenius SE & Co. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Fresenius SE & Co. has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/10/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:FSNUY
• CIK: 904868
• Web: www.fresenius.com
• Phone: (496) 172-6080
• Fax: N/A
• Employees: 178,394
• Year Founded: 1912

Profitability

• EPS (Trailing Twelve Months): $0.79
• Trailing P/E Ratio: 16.46
• Forward P/E Ratio: 12.04
• P/E Growth: N/A
• Net Income: $1.43 billion
• Net Margins: 6.67%
• Pretax Margin: 9.49%
• Return on Equity: 10.33%
• Return on Assets: 4.87%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 1.27
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $25.87 billion
• Price / Sales: 1.13
• Cash Flow: $1.57 per share
• Price / Cash Flow: 8.26
• Book Value: $9.93 per share
• Price / Book: 1.31

Miscellaneous

• Outstanding Shares: 2,252,950,000
• Free Float: N/A
• Market Cap: $29.29 billion
• Optionable: Not Optionable
• Beta: 0.62